Annual Report

Overview

The report describes the company's 2025 revenue of RMB41,498 million and total R&D expenditure of RMB5,913 million. It highlights approvals and launches for innovative drugs in China and international markets, including Serplulimab and Denosumab. The company also reports continued implementation of its AI strategy across R&D, clinical development, production, operations and commercialization.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services